Sunbird Bio, a biotechnology company developing revolutionary new assays measuring brain derived protein aggregates via extracellular vesicles that pass through the blood-brain barrier, will be presenting a poster on its latest developments on its APEX sensor platform for reliable and accurate detection of brain amyloid status from the blood at the 15th Clinical Trials On Alzheimer's Disease (CTAD), held in San Francisco, from November 29 – December 2, 2022.

Information for the poster presentation

Title: Novel technology platform for the direct and sensitive detection of circulating AD-related molecules in blood

Presented by: Carine Lim

Time/Date: Thursday, December 1, 8am – 6pm

Abstract: P117